LRRK2 and Parkinson disease: These results suggest that αSyn aggregation and propagation in PD may be linked to LRRK2 activity, and aberrant hyper-kinase activity associated with mutant LRRK2 could be a potential therapeutic target to modify disease progression in PD19.